Envoy Medical Secures Three New Patents, Strengthening Leadership in Fully Implantable Hearing Technology
Envoy Medical (NASDAQ: COCH), a hearing health company, has secured three significant patents across the United States, Australia, and Hong Kong for its fully implantable hearing technology. The patents include U.S. Patent No. 12,390,634 for a modular cochlear implant system, Australian Patent No. 2022254630 for electrode impedance diagnostics, and Hong Kong Patent No. 40101898 for cochlear implant stimulation calibration.
These patents strengthen Envoy Medical's intellectual property portfolio in developing next-generation cochlear implant solutions that provide patients with a discreet, 24/7 hearing experience without external components. The technology focuses on innovative features such as implantable batteries, communication modules, and improved electrode diagnostics.
Envoy Medical (NASDAQ: COCH), azienda nel settore dell'udito, ha ottenuto tre brevetti importanti negli Stati Uniti, in Australia e a Hong Kong per la sua tecnologia per impianti uditivi completamente impiantabili. I brevetti comprendono il U.S. Patent No. 12,390,634 per un sistema di impianto cocleare modulare, l'Australian Patent No. 2022254630 per la diagnostica dell'impedenza degli elettrodi e il Hong Kong Patent No. 40101898 per la calibrazione della stimolazione degli impianti cocleari.
Questi brevetti rafforzano il portafoglio di proprietà intellettuale di Envoy Medical nello sviluppo di soluzioni di impianto cocleare di nuova generazione che offrono ai pazienti un'esperienza uditiva discreta, H24, senza componenti esterni. La tecnologia punta su caratteristiche innovative quali batterie impiantabili, moduli di comunicazione e diagnostica migliorata degli elettrodi.
Envoy Medical (NASDAQ: COCH), una compañía dedicada a la salud auditiva, ha obtenido tres patentes importantes en Estados Unidos, Australia y Hong Kong para su tecnología de audífonos totalmente implantables. Las patentes incluyen la U.S. Patent No. 12,390,634 para un sistema modular de implante coclear, la Australian Patent No. 2022254630 para diagnóstico de impedancia de electrodos y la Hong Kong Patent No. 40101898 para la calibración de la estimulación del implante coclear.
Estas patentes fortalecen la cartera de propiedad intelectual de Envoy Medical en el desarrollo de soluciones de implantes cocleares de próxima generación que proporcionan a los pacientes una experiencia auditiva discreta, 24/7, sin componentes externos. La tecnología se centra en características innovadoras como baterías implantables, módulos de comunicación y un diagnóstico mejorado de los electrodos.
Envoy Medical (NASDAQ: COCH)는 청각 건강 기업으로서 완전 이식형 청각 기술에 대해 미국, 호주, 홍콩에서 세 건의 주요 특허를 취득했습니다. 특허에는 모듈식 인공와우 시스템에 대한 U.S. Patent No. 12,390,634, 전극 임피던스 진단에 대한 Australian Patent No. 2022254630, 인공와우 자극 보정에 대한 Hong Kong Patent No. 40101898이 포함됩니다.
이들 특허는 외부 부품 없이 환자에게 24시간 눈에 띄지 않는 청력 경험을 제공하는 차세대 인공와우 솔루션 개발에서 Envoy Medical의 지적 재산 포트폴리오를 강화합니다. 해당 기술은 이식형 배터리, 통신 모듈 및 개선된 전극 진단 등 혁신적 기능에 중점을 두고 있습니다.
Envoy Medical (NASDAQ: COCH), société spécialisée dans la santé auditive, a obtenu trois brevets importants aux États-Unis, en Australie et à Hong Kong pour sa technologie d'audition entièrement implantable. Les brevets comprennent le U.S. Patent No. 12,390,634 pour un système d'implant cochléaire modulaire, le Australian Patent No. 2022254630 pour le diagnostic d'impédance des électrodes et le Hong Kong Patent No. 40101898 pour l'étalonnage de la stimulation des implants cochléaires.
Ces brevets renforcent le portefeuille de propriété intellectuelle d'Envoy Medical dans le développement de solutions d'implants cochléaires de nouvelle génération offrant aux patients une expérience auditive discrète, 24h/24 et sans composants externes. La technologie met l'accent sur des fonctionnalités innovantes telles que des batteries implantables, des modules de communication et une meilleure diagnostique des électrodes.
Envoy Medical (NASDAQ: COCH), ein Unternehmen im Bereich Hörgesundheit, hat drei bedeutende Patente in den USA, Australien und Hongkong für seine komplett implantierbare Hörtechnologie gesichert. Zu den Patenten gehören das U.S. Patent No. 12,390,634 für ein modulares Cochlea-Implantat-System, das Australian Patent No. 2022254630 für Elektroden-Impedanzdiagnostik und das Hong Kong Patent No. 40101898 für die Kalibrierung der Stimulation von Cochlea-Implantaten.
Diese Patente stärken das geistige Eigentum von Envoy Medical bei der Entwicklung von Cochlea-Implantat-Lösungen der nächsten Generation, die Patienten ein unauffälliges, rund um die Uhr verfügbares Hörerlebnis ohne externe Komponenten bieten. Die Technologie fokussiert auf innovative Merkmale wie implantierbare Batterien, Kommunikationsmodule und verbesserte Elektroden-Diagnostik.
- Expansion of global intellectual property portfolio with three new patents
- Patents cover critical technology for fully implantable hearing solutions
- Technology eliminates need for external components, offering 24/7 hearing capability
- Strategic advancement in multiple key markets (US, Australia, Hong Kong)
- None.
Insights
Envoy Medical's three new patents strengthen IP position for fully implantable hearing solutions, enhancing competitive advantage and long-term market exclusivity.
The issuance of three new patents across the United States, Australia, and Hong Kong significantly bolsters Envoy Medical's intellectual property portfolio in the fully implantable hearing technology space. The US patent (No. 12,390,634) focuses on reducing unintended electrical communication between circuitry and cochlear electrodes—a critical advancement for improving device performance and safety. The Australian patent (No. 2022254630) addresses electrode impedance diagnostics, allowing for customized stimulation parameters based on real-time impedance measurements. The Hong Kong patent (No. 40101898) relates to calibration of current flow, enabling more precise control of electrical stimulation.
These patents collectively enhance Envoy's competitive moat in the hearing restoration market. By protecting key technological components for fully implantable cochlear implants that eliminate external components, Envoy secures exclusive rights to commercialize these innovations. The strategic geographical distribution across major markets indicates a coordinated global IP strategy. For a relatively small NASDAQ-listed medical device company, this IP portfolio expansion represents a significant barrier to entry for competitors and potential leverage for partnerships or licensing arrangements. The technical nature of these patents—focusing on electrical isolation, impedance diagnostics, and current calibration—addresses fundamental engineering challenges in creating reliable fully implantable hearing solutions, suggesting meaningful progress in their product development pipeline.
Patents issued in the U.S., Australia, and Hong Kong advance Envoy Medical's innovation pipeline and protect next-generation cochlear implant solutions for individuals living with hearing loss.
White Bear Lake, Minnesota--(Newsfile Corp. - August 20, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the issuance of three new patents across the United States, Australia, and Hong Kong. These patents expand the company's global intellectual property portfolio and mark another strategic step in delivering next-generation cochlear implant solutions that offer patients discreet, 24/7 hearing experience without the limitation of externally worn components.
The U.S. Patent & Trademark Office has issued the following patent to Envoy Medical:
- U.S. Patent No. 12,390,634, on August 19, 2025. The title of the patent is Fully Implantable Modular Cochlear Implant System. This patent relates to cochlear implant systems having a signal processor and an implantable battery and/or communication module having a signal generator that generates digital signals for communicating to the signal processor. The signal processor and the implantable battery and/or communication module include circuitry, a can that houses and surrounds the circuitry, and an impedance between the circuitry and the can to reduce unintended electrical communication between the circuitry and a cochlear electrode of the cochlear implant system.
The Australian Patent Office has issued the following patent to Envoy Medical:
- Australian Patent No. 2022254630, on July 17, 2025. The title is Cochlear Implant System with Electrode Impedance Diagnostics. This patent relates to electrode impedance diagnostics in cochlear implant systems. A cochlear implant system determines an impedance associated with a current path from a source element to a return electrode and determines one or more stimulation parameters for the source element based on the impedance. An example stimulation parameter is a compliance voltage for the source element to provide a prescribed current.
The Hong Kong Patent Office has issued the following patent to Envoy Medical:
- Hong Kong Patent No. 40101898, on May 16, 2025. The title is Cochlear Implant Stimulation Calibration. This patent relates to calibrating current flow in a cochlear implant system. A switching network is controlled to place a source element of a cochlear implant system in communication with a testing circuit. An amount of electrical current provided to the testing circuit is determined and the output of the source element is adjusted based on the determined amount of electrical current.
"Our patent portfolio has many critical building blocks to redefine what's possible for hearing restoration solutions. These additional patents strengthen our position. By expanding our global patent portfolio, Envoy Medical is not only protecting groundbreaking innovations, but also supporting our mission to deliver life-changing, fully implantable solutions to more people around the world. This momentum brings us one step closer to eliminating daily limitations faced by millions of people living with hearing loss," commented Brent Lucas, CEO of Envoy Medical.
For more information about Envoy Medical's innovation pipeline and intellectual property portfolio, visit www.envoymedical.com.
To be added to the Envoy Medical email distribution list, please email Envoy@kcsa.com with COCH in the subject line.
About Envoy Medical, Inc.
Envoy Medical (NASDAQ: COCH) is a hearing health company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life.
About the Fully Implanted Acclaim® Cochlear Implant
We believe the fully implanted Acclaim Cochlear Implant ("Acclaim CI") is a first-of-its-kind hearing device. Envoy Medical's fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.
The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.
The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019.
CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.
About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)
The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.
*Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.
Important safety information for the Esteem FI-AMEI can be found at: https://www.envoymedical.com/safety-information.
Additional Information and Where to Find It
Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC's website at www.sec.gov.
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-Looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Such statements may include, but are not limited to, statements regarding the expectations of Envoy Medical concerning the outlook for its business, productivity, plans and goals for future operational improvements and capital investments; the ability to obtain additional patents and develop future products or product improvements, the Acclaim CI being the first to market fully implanted cochlear implant, the timing and results of approvals, site documents, logistics, activations, enrollments, follow-up visits, data, and clinical trials of the Acclaim CI, and the participation or any changes in participation of any subjects, institutions, or healthcare professionals in such trials; the safety, performance, and market acceptance of the Acclaim CI; the size of Envoy Medical's addressable market, operational performance, future market conditions or economic performance and developments in the capital and credit markets and any information concerning possible or assumed future operations of Envoy Medical. The forward-looking statements contained in this press release reflect Envoy Medical's current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. Envoy Medical does not guarantee that the events described will happen as described (or that they will happen at all). These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to changes in the market price of shares of Envoy Medical's Class A Common Stock; changes in or removal of Envoy Medical's shares inclusion in any index; Envoy Medical's success in retaining or recruiting, or changes required in, its officers, key employees or directors; unpredictability in the medical device industry, the regulatory process to approve medical devices, and the clinical development process of Envoy Medical products; competition in the medical device industry, and the failure to introduce new products and services in a timely manner or at competitive prices to compete successfully against competitors; disruptions in relationships with Envoy Medical's suppliers, or disruptions in Envoy Medical's own production capabilities for some of the key components and materials of its products; changes in the need for capital and the availability of financing and capital to fund these needs; changes in interest rates or rates of inflation; legal, regulatory and other proceedings could be costly and time-consuming to defend; changes in applicable laws or regulations, or the application thereof on Envoy Medical; a loss of any of Envoy Medical's key intellectual property rights or failure to adequately protect intellectual property rights; the effects of catastrophic events, including war, terrorism and other international conflicts; and other risks and uncertainties set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in the Annual Report on Form 10-K filed by Envoy Medical on March 31, 2025, and in other reports Envoy Medical files, with the SEC. If any of these risks materialize or Envoy Medical's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While forward-looking statements reflect Envoy Medical's good faith beliefs, they are not guarantees of future performance. Envoy Medical disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Envoy Medical.
###
Investor Contact:
Phil Carlson
KCSA Strategic Communications
O: 212.896.1233
E: Envoy@kcsa.com
Media Contact:
Anne Donohoe
KCSA Strategic Communications
O: 732-620-0033
E: Envoy@kcsa.com
SOURCE: Envoy Medical, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/263072
FAQ
What new patents did Envoy Medical (NASDAQ: COCH) receive in 2025?
How do Envoy Medical's new cochlear implant patents benefit patients?
What is unique about Envoy Medical's patented cochlear implant technology?
Which countries granted patents to Envoy Medical for their hearing technology?
